Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07121829 · ClinicalTrials.gov registry record · Phase 1
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
A Phase 1 study, sponsored by Day One Biopharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT07121829 is a Phase 1 study that was terminated before completion, run by Day One Biopharmaceuticals. The registered enrollment target is 44 participants.
The verdict
NCT07121829, a Phase 1 study, was terminated before completion, sponsored by Day One Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of the MAPK pathway, such as tumors that harbor RAS or RAF alterations. \*Note: Study concluded as Phase 1b only.
Interventions
- DRUG Tovorafenib
- DRUG Tovorafenib Drug: Pimasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-05-02 |
| Est. Completion | 2024-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07121829
The ClinicalTrials.gov registry entry for NCT07121829 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Day One Biopharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tovorafenib is the first listed.
NCT07121829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07121829 about?
NCT07121829 is a clinical study titled "Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors". This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of the MAPK pathway, such as tumors that harbor RAS or RAF alterations. \*N...
What is the current status of trial NCT07121829?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2022-05-02. Estimated completion is 2024-12-18.
What interventions are being tested in trial NCT07121829?
The interventions under investigation include: Tovorafenib (DRUG), Tovorafenib Drug: Pimasertib (DRUG).
Who is sponsoring clinical trial NCT07121829?
This trial is sponsored by Day One Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.